ER-CCDC170 fusion
|
Breast Cancer
|
ER-CCDC170 fusion
|
Breast Cancer
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
ER-CCDC170 fusion
|
Breast Cancer
|
ER-CCDC170 fusion
|
Breast Cancer
|
dasatinib + lapatinib Sensitive: D – Preclinical
|
dasatinib + lapatinib Sensitive: D – Preclinical
|
ER-CCDC170 fusion
|
Breast Cancer
|
ER-CCDC170 fusion
|
Breast Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|